GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results for GSK
-13.22 (-1.01%)
Oct 7 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,282.50 - 1,312.00
52 week 1,227.50 - 1,645.00
Open 1,305.50
Vol / Avg. 10.64M/8.42M
Mkt cap 62.94B*
P/E 6.45
Div/yield 19.00/6.19*
EPS 2.01*
Shares 4.87B
Beta     -
Inst. own     -
Nov 3, 2015
GlaxoSmithKline PLC R&D Meeting Add to calendar
Oct 28, 2015
Q3 2015 GlaxoSmithKline PLC Earnings Release - 8:00AM GMT - Add to calendar
Jul 29, 2015
Q2 2015 GlaxoSmithKline PLC Earnings Call
Jul 29, 2015
Q2 2015 GlaxoSmithKline PLC Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 1.95% 12.31%
Operating margin 5.71% 15.64%
EBITD margin - 28.70%
Return on average assets 0.82% 6.84%
Return on average equity 8.39% 48.95%
Employees 98,702 -
CDP Score - 96 B


980 Great West Road
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSK's Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSK's Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 50
Simon Dingemans Chief Financial Officer, Executive Director
Age: 51
Moncef Slaoui Chairman - Global Vaccines, Executive Director
Age: 55
Roger Connor President - Global Manufacturing & Supply
Abbas Hussain President, Global Pharmaceuticals
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 49
Patrick Vallance President - Pharmaceuticals R&D
Emma Walmsley President - Consumer Healthcare Worldwide
Daniel Troy Senior Vice President, General Counsel
Claire Thomas Senior Vice President - Human Resources